https://doi.org/10.4081/monaldi.2026.3980
Effect of glucagon-like-peptide-1 receptor agonists on major cardiovascular outcomes: a systematic review and meta-analysis
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Accepted: 22 June 2026
Published: 26 October 2026
Glucagon-like-peptide-1 (GLP-1) receptor agonists are an antihyperglycemic group of drugs that have emerged as potentially preventing the risk of cardiovascular events. This meta-analysis assesses the effect of GLP-1 receptor agonists on cardiovascular outcomes. A detailed search of existing literature was based on MEDLINE, the Cochrane Library, Embase, and ClinicalTrials.gov. The search included all the studies from inception to February 2026. Statistical analyses were performed using the RevMan software, and a random-effects model was used to conduct the meta-analysis. Data were represented via forest plots, and dichotomous outcomes were evaluated using the Mantel-Haenszel method. This meta-analysis includes 12 randomized control trials (RCTs) with 82,669 patients. The analysis showed that GLP-1 receptor agonists reduce risk of cardiac death [relative risk (RR): 0.89, 95% confidence interval (CI): 0.82-0.96, p=0.003, I²=0%], all-cause mortality (RR: 0.88, 95% CI: 0.84-0.93, p<0.00001, I²=0%), stroke (RR: 0.85, 95% CI: 0.77-0.94, p=0.001, I²=0%), non-fatal stroke (RR: 0.87, 95% CI: 0.79-0.96, p=0.005, I²=0%) and revascularization (RR: 0.82, 95% CI: 0.72-0.95, p=0.007, I²=59%). There was no statistically significant reduction in myocardial infarction (MI) (RR: 0.92, 95% CI: 0.84-1.01, p=0.09, I²=42%), fatal MI (RR: 1.15, 95% CI: 0.80-1.66, p=0.44, I²=0%), non-fatal MI (RR: 0.91, 95% CI: 0.82-1.01, p=0.09, I²=51%), fatal stroke (RR: 0.75, 95% CI: 0.55-1.00, p=0.05, I²=0%), heart failure hospitalization (RR: 0.94, 95% CI: 0.85-1.03, p=0.20, I²=17%), or hospitalization for unstable angina (RR: 0.97, 95% CI: 0.85-1.12, p=0.71, I²=0%). This meta-analysis demonstrates that GLP-1 receptor agonists have a significant impact on cardiovascular death. More thorough RCTs with longer follow-up periods are required to completely understand the possible cardiovascular advantages of GLP-1 receptor agonists.
Downloads
GBD 2021 Forecasting Collaborators. Burden of disease scenarios for 204 countries and territories, 2022-2050: a forecasting analysis for the Global Burden of Disease Study 2021. Lancet 2024;403:2204-56. DOI: https://doi.org/10.1016/S0140-6736(24)00685-8
Kovesdy CP. Epidemiology of chronic kidney disease: an update 2022. Kidney Int Suppl 2022;12:7-11. DOI: https://doi.org/10.1016/j.kisu.2021.11.003
Ong KL, Stafford LK, McLaughlin SA, et al. Global, regional, and national burden of diabetes from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet 2023;402:203-34. DOI: https://doi.org/10.1016/S0140-6736(23)01301-6
Ronco C, Haapio M, House AA, et al. Cardiorenal syndrome. J Am Coll Cardiol 2008;52:1527-39. DOI: https://doi.org/10.1016/j.jacc.2008.07.051
Tariq S, Ali MA, Hassan Iftikhar HM, et al. Long-term cardiovascular outcomes of glucagon-like peptide-1 (GLP-1) receptor agonists in type 2 diabetes: a systematic review. Cureus 2024;16:e73705. DOI: https://doi.org/10.7759/cureus.73705
Sattar N, Lee MMY, Kristensen SL, et al. Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of randomised trials. Lancet Diabetes Endocrinol 2021;9:653-62. DOI: https://doi.org/10.1016/S2213-8587(21)00203-5
Ferhatbegovic L, Mršic D, Macic-Džankovic A. The benefits of GLP1 receptors in cardiovascular diseases. Front Clin Diabetes Healthc 2023;4:1293926. DOI: https://doi.org/10.3389/fcdhc.2023.1293926
Cochrane handbook for systematic reviews of interventions. Available from: https://training.cochrane.org/handbook
Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ 2021;372:n71. DOI: https://doi.org/10.1136/bmj.n71
Hernandez AF, Green JB, Janmohamed S, et al. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial. Lancet 2018;392:1519-29. DOI: https://doi.org/10.1016/S0140-6736(18)32261-X
Gerstein HC, Sattar N, Rosenstock J, et al. Cardiovascular and renal outcomes with efpeglenatide in type 2 diabetes. N Engl J Med 2021;385:896-907. DOI: https://doi.org/10.1056/NEJMoa2108269
Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet 2019;394:121-30. DOI: https://doi.org/10.1016/S0140-6736(19)31149-3
Marso SP, Baeres FMM, Bain SC, et al. Effects of liraglutide on cardiovascular outcomes in patients with diabetes with or without heart failure. J Am Coll Cardiol 2020;75:1128-41. DOI: https://doi.org/10.1016/j.jacc.2019.12.063
Margulies KB, Hernandez AF, Redfield MM, et al. Effects of liraglutide on clinical stability among patients with advanced heart failure and reduced ejection fraction: a randomized clinical trial. JAMA 2016;316:500-8. DOI: https://doi.org/10.1001/jama.2016.10260
Holman RR, Bethel MA, Mentz RJ, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med 2017;377:1228-39. DOI: https://doi.org/10.1056/NEJMoa1612917
Pfeffer MA, Claggett B, Diaz R, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 2015;373:2247-57. DOI: https://doi.org/10.1056/NEJMoa1509225
Husain M, Birkenfeld AL, Donsmark M, et al. Oral semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2019;381:841-51. DOI: https://doi.org/10.1056/NEJMoa1901118
Lincoff AM, Brown-Frandsen K, Colhoun HM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med 2023;389:2221-32. DOI: https://doi.org/10.1056/NEJMoa2307563
Marso SP, Bain SC, Consoli A, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med 2016;375:1834-44. DOI: https://doi.org/10.1056/NEJMoa1607141
Kosiborod Mikhail N, Abildstrøm Steen Z, Borlaug Barry A, et al. Semaglutide in patients with heart failure with preserved ejection fraction and obesity. N Engl J Med 2023;389:1069-84. DOI: https://doi.org/10.1056/NEJMc2312296
Ruff CT, Baron M, Im K, et al. Subcutaneous infusion of exenatide and cardiovascular outcomes in type 2 diabetes: a non-inferiority randomized controlled trial. Nat Med 2022;28:89-95. DOI: https://doi.org/10.1038/s41591-021-01584-3
Bethel MA, Patel RA, Merrill P, et al. Cardiovascular outcomes with glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes: a meta-analysis. Lancet Diabetes Endocrinol 2018;6:105-13. DOI: https://doi.org/10.1016/S2213-8587(17)30412-6
Rivera FB, Cruz LLA, Magalong JV, et al. Cardiovascular and renal outcomes of glucagon-like peptide 1 receptor agonists among patients with and without type 2 diabetes mellitus: A meta-analysis of randomized placebo-controlled trials. Am J Prev Cardiol 2024;18:100679. DOI: https://doi.org/10.1016/j.ajpc.2024.100679
de Oliveira Almeida G, Nienkötter TF, Balieiro CCA, et al. Cardiovascular benefits of glp-1 receptor agonists in patients living with obesity or overweight: a meta-analysis of randomized controlled trials. Am J Cardiovasc Drugs 2024;24:509-21. DOI: https://doi.org/10.1007/s40256-024-00647-3
Stefanou MI, Palaiodimou L, Theodorou A, et al. Risk of major adverse cardiovascular events and all-cause mortality under treatment with GLP-1 RAs or the dual GIP/GLP-1 receptor agonist tirzepatide in overweight or obese adults without diabetes: a systematic review and meta-analysis. Ther Adv Neurol Disord 2024;17:17562864241281903. DOI: https://doi.org/10.1177/17562864241281903
Wilding JPH, Batterham RL, Calanna S, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med 2021;384:989-1002. DOI: https://doi.org/10.1056/NEJMoa2032183
Lee YS, Jun HS. Anti-inflammatory effects of GLP-1-based therapies beyond glucose control. Mediators Inflamm 2016;2016:3094642. DOI: https://doi.org/10.1155/2016/3094642
Bogers RP, Bemelmans WJE, Hoogenveen RT, et al. Association of overweight with increased risk of coronary heart disease partly independent of blood pressure and cholesterol levels: a meta-analysis of 21 cohort studies including more than 300 000 persons. Arch Intern Med 2007;167:1720-8. DOI: https://doi.org/10.1001/archinte.167.16.1720
Global Burden of Metabolic Risk Factors for Chronic Diseases Collaboration. Metabolic mediators of the effects of body-mass index, overweight, and obesity on coronary heart disease and stroke: a pooled analysis of 97 prospective cohorts with 1·8 million participants. Lancet 2014;383:970-83. DOI: https://doi.org/10.1016/S0140-6736(13)61836-X
Van Gaal LF, Mertens IL, De Block CE. Mechanisms linking obesity with cardiovascular disease. Nature 2006;444:875-80. DOI: https://doi.org/10.1038/nature05487
Kitzman DW, Nicklas BJ. Pivotal role of excess intra-abdominal adipose in the pathogenesis of metabolic/obese HFpEF. JACC Heart Fail 2018;6:1008-10. DOI: https://doi.org/10.1016/j.jchf.2018.08.007
Kosiborod MN, Bhatta M, Davies M, et al. Semaglutide improves cardiometabolic risk factors in adults with overweight or obesity: STEP 1 and 4 exploratory analyses. Diabetes Obes Metab 2023;25:468-78. DOI: https://doi.org/10.1111/dom.14890
Wei Y, Mojsov S. Tissue-specific expression of the human receptor for glucagon-like peptide-I: brain, heart and pancreatic forms have the same deduced amino acid sequences. FEBS Lett 1995;358:219-24. DOI: https://doi.org/10.1016/0014-5793(94)01430-9
Nauck M. Incretin therapies: highlighting common features and differences in the modes of action of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors. Diabetes Obes Metab 2016;18:203-16. DOI: https://doi.org/10.1111/dom.12591
Steinert RE, Beglinger C, Langhans W. Intestinal GLP-1 and satiation: from man to rodents and back. Int J Obes 2016;40:198-205. DOI: https://doi.org/10.1038/ijo.2015.172
Hubert HB, Feinleib M, McNamar PM, Castelli WP. Obesity as an independent risk factor for cardiovascular disease: a 26-year follow-up of participants in the Framingham Heart Study. Available from: https://www.ahajournals.org/doi/epdf/10.1161/01.CIR.67.5.968
Yusuf S, Hawken S, Ounpuu S, et al. Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. Lancet 2005;366:1640-9. DOI: https://doi.org/10.1016/S0140-6736(05)67663-5
Malhotra K, Katsanos AH, Lambadiari V, et al. GLP-1 receptor agonists in diabetes for stroke prevention: a systematic review and meta-analysis. J Neurol 2020;267:2117-22. DOI: https://doi.org/10.1007/s00415-020-09813-4
Giugliano D, Chiodini P, Maiorino MI, et al. Cardiovascular outcome trials and major cardiovascular events: does glucose matter? A systematic review with meta-analysis. J Endocrinol Invest 2019;42:1165-9. DOI: https://doi.org/10.1007/s40618-019-01047-0
Guo X, Sang C, Tang R, et al. Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes. Diabetes Obes Metab 2023;25:53-63. DOI: https://doi.org/10.1111/dom.15043
Caruso I, Cignarelli A, Sorice GP, et al. Cardiovascular and renal effectiveness of GLP-1 receptor agonists vs. other glucose-lowering drugs in type 2 diabetes: a systematic review and meta-analysis of real-world studies. Metabolites 2022;12:183. DOI: https://doi.org/10.3390/metabo12020183
How to Cite
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.